EDP Sciences logo
Subscriber Authentication Point
Search
Menu
Home All issues Volume 38 / No 12 (Décembre 2022) Med Sci (Paris), 38 12 (2022) 1052-1060 References
Open Access
Issue
Med Sci (Paris)
Volume 38, Number 12, Décembre 2022
Un monde de virus
Page(s) 1052 - 1060
Section M/S Revues
DOI https://doi.org/10.1051/medsci/2022168
Published online 13 December 2022
  1. Tangy F, Tournier JN. L’homme façonné par les virus. Paris : Édition Odile Jacob, 2021. [Google Scholar]
  2. Tournier JN, Tangy F. Les vaccins pour les nuls Paris: Édition First, 2017. [Google Scholar]
  3. Tangy F, Tournier JN. Le petit livre des vaccins. Paris : Édition First, 2022. [Google Scholar]
  4. Chaudhary N, Weissman D, Whitehead KA. mRNA Vaccines for Infectious Diseases: Principles, Delivery and Clinical Translation. Nat Rev Drug Discov 2021; 20 : 817–38. [CrossRef] [PubMed] [Google Scholar]
  5. Jackson NAC, Kester KE, Casimiro D, et al. The Promise of mRNA Vaccines: A Biotech and Industrial Perspective. NPJ Vaccines 2020; 5 : 11. [CrossRef] [PubMed] [Google Scholar]
  6. Pardi N, Hogan MJ, Porter FW et al. mRNA vaccines – a new era in vaccinology. Nat Rev Drug Discov 2018 ; 17 : 261–279. [CrossRef] [PubMed] [Google Scholar]
  7. Meslé MM, Brown J, Mook P, et al. Estimated Number of Deaths Directly Averted in People 60 Years and Older as a Result of COVID-19 Vaccination in the WHO European Region, December 2020 to November 2021. Eurosurveillance 2021; 26 : 2101021. [Google Scholar]
  8. https://covid19.who.int. [Google Scholar]
  9. Roldão A, Mellado MCM, Castilho LR et al. Virus-like particles in vaccine development. Expert Rev Vaccines 2010 ; 9 : 1149–1176. [CrossRef] [PubMed] [Google Scholar]
  10. Rappuoli R, Bottomley MJ, D’Oro U et al. Reverse vaccinology 2.0: Human immunology instructs vaccine antigen design. J Exp Med 2016 ; 213 : 469–481. [CrossRef] [PubMed] [Google Scholar]
  11. Dormitzer PR, Grandi G, Rappuoli R. Structural vaccinology starts to deliver. Nat Rev Microbiol 2012 ; 10 : 807–813. [CrossRef] [PubMed] [Google Scholar]
  12. Travieso T, Li J, Mahesh S, et al. The use of viral vectors in vaccine development. NPJ Vaccines 2022; 7 : 75. [CrossRef] [PubMed] [Google Scholar]
  13. Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med 2020; 383 : 2603–15. [CrossRef] [PubMed] [Google Scholar]
  14. Falsey AR, Sobieszczyk ME, Hirsch I, et al. Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine. N Engl J Med 2021; 385 : 2348–60. [CrossRef] [PubMed] [Google Scholar]
  15. Lauring AS, Jones JO, Andino R. Rationalizing the development of live attenuated virus vaccines. Nat Biotechnol 2010 ; 28 : 573–579. [CrossRef] [PubMed] [Google Scholar]
  16. Moratorio G, Henningsson R, Barbezange C et al. Attenuation of RNA viruses by redirecting their evolution in sequence space. Nat Microbiol 2017 ; 2 : 17088. [CrossRef] [PubMed] [Google Scholar]
  17. He F, Madhan S, Kwang J. Baculovirus vector as a delivery vehicle for influenza vaccines. Expert Rev Vaccines 2009 ; 8 : 455–467. [CrossRef] [PubMed] [Google Scholar]
  18. Maharjan PM, Choe S. Plant-Based COVID-19 Vaccines: Current Status, Design, and Development Strategies of Candidate Vaccines. Vaccines 2021; 9 : 992. [CrossRef] [PubMed] [Google Scholar]
  19. Robert-Guroff M.. Replicating and non-replicating viral vectors for vaccine development. Curr Opin Biotechnol 2007 ; 18 : 546–556. [CrossRef] [PubMed] [Google Scholar]
  20. Prow NA, Jimenez Martinez R, Hayball JD et al. Poxvirus-based vector systems and the potential for multi-valent and multi-pathogen vaccines. Expert Rev Vaccines 2018 ; 17 : 925–934. [CrossRef] [PubMed] [Google Scholar]
  21. Coughlan L, Kremer EJ, Shayakhmetov DM. Adenovirus-based vaccines-a platform for pandemic preparedness against emerging viral pathogens. Mol Ther 2022; 30 : 1822–49. [CrossRef] [PubMed] [Google Scholar]
  22. Frantz PN, Teeravechyan S, Tangy F. Measles-derived vaccines to prevent emerging viral diseases. Microbes Infect 2018 ; 20 : 493–500. [CrossRef] [PubMed] [Google Scholar]
  23. Monath TP, Seligman SJ, Robertson JS et al. Live virus vaccines based on a yellow fever vaccine backbone: standardized template with key considerations for a risk/benefit assessment. Vaccine 2015 ; 33 : 62–72. [CrossRef] [PubMed] [Google Scholar]
  24. Henao-Restrepo AM, Camacho A, Longini IM et al. Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit !). Lancet 2017 ; 389 : 505–518. [CrossRef] [PubMed] [Google Scholar]
  25. Sette A, Crotty S. Immunological memory to SARS-CoV-2 infection and COVID-19 vaccines. Immunol Rev 2022 Jun 22. DOI: 10.1111/imr.13089. [PubMed] [Google Scholar]
  26. https://www.cancer.org/research/cancer-facts-statistics/global.html. [Google Scholar]
  27. Lauer UM, Beil J. Oncolytic viruses: challenges and considerations in an evolving clinical landscape. Future Oncol 2022 Jul 12. DOI: 10.2217/fon-2022-0440. [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.